نتایج جستجو برای: induced liver injury dili

تعداد نتایج: 1452682  

2016
Abhasnee Sobhonslidsuk Kittiyod Poovorawan Ngamphol Soonthornworasiri Wirichada Pan-Ngum Kamthorn Phaosawasdi

BACKGROUND Toxic liver diseases are mainly caused by drug-induced liver injury (DILI). We assessed incidences and outcomes of DILI including associated factors for mortality. METHODS We performed a population-based study of hospitalized patients with DILI. Information was retrieved from the Nationwide Hospital Admission Data using ICD-10 code of toxic liver diseases (K71) and additional codes...

Introduction: In many cultures fasting is recommended as a way to protect and promote health. However, there are few studies on the effects of fasting on organ function and resistance to toxic agents such as drugs. This study was conducted to investigate the effect of short-term periodic fasting on the acetaminophen hepatotoxic effects in mice. Methods: In this...

2017
Valentina Peta Chantal Tse Hugo Perazzo Mona Munteanu Yen Ngo An Ngo Nittia Ramanujam Lea Verglas Maxime Mallet Vlad Ratziu Dominique Thabut Marika Rudler Vincent Thibault Ina Schuppe-Koistinen Dominique Bonnefont-Rousselot Bernard Hainque Françoise Imbert-Bismut Michael Merz Gerd Kullak-Ublick Raul Andrade Florian van Boemmel Eckart Schott Thierry Poynard

BACKGROUND There is a clear need for better biomarkers of drug-induced-liver-injury (DILI). AIMS We aimed to evaluate the possible prognostic value of ActiTest and FibroTest proteins apoliprotein-A1, haptoglobin and alpha-2-macroglobulin, in patients with DILI. METHODS We analyzed cases and controls included in the IMI-SAFE-T-DILI European project, from which serum samples had been stored i...

Journal: :Molecular medicine reports 2012
Ling-Min Li Lei Chen Guo-Hong Deng Wen-Ting Tan Yun-Jie Dan Rong-Quan Wang Wen-Sheng Chen

The organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1) plays an important role in the transport of endogenous and xenobiotic compounds, such as bile acids and rifampin. In this study, the association between OATP1B1 polymorphisms and rifampin hepatotoxicity was investigated using integrated population genetic analysis and functional studies. A total of 273 unrelated patien...

2014
Eugenia Ulzurrun Camilla Stephens Francisco Ruiz-Cabello Mercedes Robles-Diaz Pablo Saenz-López Hacibe Hallal German Soriano Eva Roman M. Carmen Fernandez M. Isabel Lucena Raúl J. Andrade

BACKGROUND AND AIMS Flawed ABC transporter functions may contribute to increased risk of drug-induced liver injury (DILI). We aimed to analyse the influence of genetic variations in ABC transporters on the risk of DILI development and clinical presentations in a large Spanish DILI cohort. METHODS A total of ten polymorphisms in ABCB1 (1236T>C, 2677G>T,A, 3435T>C), ABCB4 (1954A>G) and ABCC2 (-...

2014
Getnet Yimer Marcus Gry Wondwossen Amogne Eyasu Makonnen Abiy Habtewold Zelalem Petros Getachew Aderaye Ina Schuppe-Koistinen Lars Lindquist Eleni Aklillu

OBJECTIVES To evaluate the incidence, type, severity and predictors of antiretroviral and/or anti-tuberculosis drugs induced liver injury (DILI). METHODS A total of 1,060 treatment naive patients were prospectively enrolled into four treatment groups: HIV patients receiving efavirenz based HAART alone (Arm-1); TB-HIV co-infected patients with CD4≤200 cells/μL, receiving concomitant rifampicin...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004
Mark S Sulkowski

Since their introduction, hepatotoxicity has been associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors (PIs). However, the complexity of the HIV-infected patient and the combinations of medications used to treat HIV complicate the understanding of the independent effects of PIs in the development of drug-induced liver injury (DILI). I discuss the current understan...

2012
Mathieu Porceddu Nelly Buron Célestin Roussel Gilles Labbe Bernard Fromenty Annie Borgne-Sanchez

Drug-induced liver injury (DILI) in humans is difficult to predict using classical in vitro cytotoxicity screening and regulatory animal studies. This explains why numerous compounds are stopped during clinical trials or withdrawn from the market due to hepatotoxicity. Thus, it is important to improve early prediction of DILI in human. In this study, we hypothesized that this goal could be achi...

2017
Gerd A. Kullak-Ublick Michael Merz Louis Griffel Neil Kaplowitz Paul Watkins

The FDA guidance for industry in the premarketing clinical evaluation of drug-induced liver injury (DILI) is the most specific regulatory guidance currently available and has been useful in setting standards for the great majority of clinical indications involving subjects with a low risk of liver disorders. However, liver safety assessment faces challenges in populations with underlying liver ...

Journal: :Alimentary pharmacology & therapeutics 2010
R Vuppalanchi P H Hayashi N Chalasani R J Fontana H Bonkovsky R Saxena D Kleiner J H Hoofnagle

BACKGROUND Case reports suggest that duloxetine hepatotoxicity may arise, but risk factors, presenting features and clinical course are not well-described. AIM To describe the presenting features and outcomes of seven well-characterized patients with suspected duloxetine hepatotoxicity. METHODS Patients enrolled in the Drug-Induced Liver Injury Network Prospective Study underwent an extensi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید